Rewrite Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2023	Feb. 28, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Feb. 28, 2023
Business Acquisition [Line Items]
Research and development			$ 435,069	$ 419,979	$ 229,807
Common stock, shares issued			92,997,158	87,103,007
Rewrite Therapeutics Delaware Corporation [Member]
Business Acquisition [Line Items]
Upfront consideration payable in cash		$ 45,000
Research and development		56,000
Milestone payments		155,000
Cash		$ 130,000
Common stock, shares issued		25,000,000
Liability for milestone payment	$ 25,000	$ 10,500
Rewrite Therapeutics Delaware Corporation [Member] | Pre-specified Research Milestones [Member]
Business Acquisition [Line Items]
Milestone payments		55,000
Rewrite Therapeutics Delaware Corporation [Member] | Regulatory Approval Milestone [Member]
Business Acquisition [Line Items]
Milestone payments		$ 100,000
Rewrite Therapeutics Delaware Corporation [Member] | Rewrite Acquisition [Member]
Business Acquisition [Line Items]
Cash						$ 900
Common stock, shares issued in connection with research milestone	567,045